Clinical impact of the metabolic phenotype of prostate cancer: role of monocarboxylate transporters (MCTs)

Similar Items

• Lactate Transporters in the Context of Prostate Cancer Metabolism: What Do We Know?
  od: Nelma Pértega-Gomes, i dr.
  Izdano: (2014-10-01)
• Lactate Transporters in the Context of Prostate Cancer Metabolism: What Do We Know?
  od: Pértega-Gomes, Nelma, i dr.
  Izdano: (2014)
• Monocarboxylate transporter 4 (MCT4) and CD147 overexpression is associated with poor prognosis in prostate cancer
  od: Pértega-Gomes, Nelma, i dr.
  Izdano: (2011)
• Monocarboxylate transporters (MCTs) in gliomas: expression and exploitation as therapeutic targets
  od: Miranda-Gonçalves, Vera, i dr.
  Izdano: (2013)
• A glycolytic phenotype is associated with prostate cancer progression and aggressiveness: a role for monocarboxylate transporters as metabolic targets for therapy
  od: Pertega‐Gomes, Nelma, i dr.
  Izdano: (2015)